Enlitic (ASX:ENL) Releases Ensight v2.3 with 12 Applications and Sectra Integration

Aditi Sarkar

06 October 2026 03:12 PM AEDT

Enlitic (ASX:ENL) Releases Ensight v2.3 with 12 Applications and Sectra Integration

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Ensight v2.3 expands commercial applications from 8 to 12.
New integration with Sectra PACS, which handles over 170 million imaging exams annually.
Third major OEM integration in customer validation, with announcement expected before year-end.
Five more commercial applications planned for 2027.

Enlitic, Inc. (ASX:ENL) has launched Ensight v2.3, the latest version of its AI-driven medical imaging data standardisation platform, increasing its commercial applications from eight to 12.

New Applications and Features

Four new commercial features were added: Productivity and Operational Analytics, Mass Archive Standardisation, Integrated Migration and Archive Standardisation, and Standardised Data for Automated Case Allocation. The release also includes a new Export API and improved AI models for X-ray imaging and de-identification.

Existing customers can subscribe to the expanded applications without infrastructure changes, giving the company opportunities to grow annualised Recurring Revenue (ARR).

Sectra Integration Expands OEM Reach

The release integrates Ensight with Sectra PACS, a global imaging provider managing more than 170 million imaging exams each year across over 2,500 health system sites. This complements the existing Intelerad integration.

A third major OEM integration is in customer validation testing, with an announcement expected before the end of 2026.

Growth Strategy and Outlook

CEO Michael Sistenich said the release expands both what the company can sell and where it can deploy. The integrated migration capability allows Ensight to be deployed during archive migrations, creating a pathway from project work into recurring revenue.

Five additional applications are planned for 2027, covering RadLex and SNOMED CT code output, procedure code inferencing, billing and coding optimisation, and research data management.

Key Takeaways

Ensight v2.3 lifts commercial applications to 12 and adds new analytics and migration tools.
Sectra PACS integration broadens the company's OEM channel.
A third OEM integration and five new 2027 applications are in the pipeline.

FAQs

Q: What did Enlitic announce?

A:The release of Ensight v2.3 with 12 commercial applications and Sectra integration.

Q: What is Ensight?

A:An AI-driven platform for standardising medical imaging data.

Q: Why is the Sectra integration important?

A:Sectra manages over 170 million imaging exams annually across 2,500+ sites.

Q: Is another OEM integration coming?

A:Yes, a third is in validation, with an announcement expected before year-end 2026.

Q: What is planned for 2027?

A:Five additional commercial applications.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.